⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.
TORNTPHARM - Swing Trade Analysis with AI Signals
Back to ListSwing Trade Rating: 4.2
| Stock Code | TORNTPHARM | Market Cap | 1,50,267 Cr. | Current Price | 4,446 ₹ | High / Low | 4,714 ₹ |
| Stock P/E | 67.9 | Book Value | 250 ₹ | Dividend Yield | 0.85 % | ROCE | 19.8 % |
| ROE | 27.6 % | Face Value | 5.00 ₹ | DMA 50 | 4,364 ₹ | DMA 200 | 4,027 ₹ |
| Chg in FII Hold | 0.05 % | Chg in DII Hold | -0.09 % | PAT Qtr | 504 Cr. | PAT Prev Qtr | 584 Cr. |
| RSI | 51.7 | MACD | 35.1 | Volume | 3,22,273 | Avg Vol 1Wk | 3,89,389 |
| Low price | 3,140 ₹ | High price | 4,714 ₹ | PEG Ratio | 2.32 | Debt to equity | 1.69 |
| 52w Index | 82.9 % | Qtr Profit Var | 2.49 % | EPS | 64.8 ₹ | Industry PE | 32.1 |
📈 Optimal Entry Price: 4,400–4,450 ₹ (near 50 DMA support)
📉 Exit Strategy: If already holding, consider exiting near 4,650–4,700 ₹ (recent high resistance) or cut losses if price falls below 4,350 ₹.
Positive
- 📊 Strong ROE (27.6%) and ROCE (19.8%) indicate efficient capital use.
- 📈 EPS at 64.8 ₹ supports valuation strength.
- 📉 PAT stability (504 Cr. vs 584 Cr.) with slight variation (+2.49%).
- 📊 RSI at 51.7 reflects balanced momentum.
- 📈 MACD positive at 35.1, confirming bullish crossover.
- 📊 Institutional confidence with FII (+0.05%) stake increase.
Limitation
- ⚠️ High P/E ratio (67.9) compared to industry PE (32.1), indicating valuation premium.
- 📉 Debt-to-equity ratio at 1.69 adds leverage risk.
- 📊 Dividend yield at 0.85% is modest.
- 📉 DII holdings decreased (-0.09%), showing reduced domestic support.
- ⚠️ Trading volume (3.22 lakh) lower than weekly average (3.89 lakh), showing reduced liquidity.
Company Negative News
- ❌ Valuation stretched relative to industry benchmarks.
- ⚠️ Leverage risk with debt-to-equity above 1.5.
Company Positive News
- ✅ EPS strength and consistent profitability.
- 📈 Institutional investors marginally increasing stake.
- 📊 Strong 52-week performance (+82.9%).
Industry
- 🌐 Industry PE at 32.1 is much lower, highlighting TORNTPHARM’s valuation premium.
- 📊 Pharma sector remains resilient with strong demand drivers and defensive characteristics.
Conclusion
⚖️ TORNTPHARM is a strong swing trade candidate with robust fundamentals and bullish technicals. Entry near 4,400–4,450 ₹ offers favorable risk-reward, with upside potential toward 4,650–4,700 ₹. Traders should apply strict stop-loss discipline below 4,350 ₹ due to high valuation and leverage risks.
This analysis frames TORNTPHARM as a premium-valued but technically strong swing candidate. Would you like me to extend this into a pharma sector overlay comparing peers like Sun Pharma and Dr. Reddy’s to benchmark its swing potential?